Oncolytics Biotech Inc
ONCY Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$0.46
KIRA · Stoqly’s AI analyst, in plain words
- Oncolytics Biotech Inc lost $28.8M in fiscal 2025.
- Free cash flow was −$20.1M in fiscal 2025, — of revenue.
Market cap
$55.4M
P/E
—
Revenue
—
Net income
−$28.8M
Free cash flow
−$20.1M
Operating margin
—
Oncolytics Biotech Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$28.8M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Oncolytics Biotech Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- ONCOLYTICS BIOTECH INC
- CIK
- 0001129928
Oncolytics Biotech Inc · ONCY
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$22.8M | −$28.8M |
| Diluted EPS | −$0.30 | −$0.30 |
| Cash | ||
| Cash from operations | −$19.9M | −$20.1M |
| Capital expenditure | $0.2M | $0.0M |
| Free cash flow | −$20.1M | −$20.1M |
| Share count change | — | 25.3% |
| Debt and strength | ||
| Cash and short-term investments | $11.1M | $5.2M |
| Shareholders' equity | $3.3M | −$3.8M |
| Current ratio | 2.5x | 1.1x |
| Returns and quality | ||
| Return on equity | −691.1% | — |
| Return on tangible equity | −691.1% | — |
| Altman Z'' | −106.1 | −209.8 |
Insiders bought, 12 months
$0.4M
10 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Oncolytics Biotech Inc · ONCY
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.46 a share, the company is worth $55.4M.
Source: SEC EDGAR XBRL filings (CIK 0001129928). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.